Clinical bottom line
Deprescribing is a critical strategy in managing polypharmacy among older adults, aiming to reduce medication burden and associated risks while maintaining or improving quality of life. Effective deprescribing involves a systematic approach to identifying and discontinuing medications that are no longer necessary or potentially harmful. Evidence supports the benefits of deprescribing in reducing adverse drug events, improving medication adherence, and enhancing overall health outcomes. However, successful implementation requires careful consideration of individual patient contexts, ongoing monitoring, and collaboration among healthcare providers.
What the evidence shows
Polypharmacy, defined as the use of multiple medications, is prevalent among older adults and associated with increased risks of adverse drug events, hospitalizations, and mortality. A systematic review by Reeve et al. (2017) highlights that deprescribing interventions can effectively reduce medication burden and improve clinical outcomes in older populations [PMID: 28545379].
The D-PRESCRIBE trial (2018) demonstrated that a structured deprescribing intervention, involving pharmacist-led medication reviews and patient education, significantly reduced the use of inappropriate medications among older adults in primary care settings [PMID: 30389663]. This trial underscores the role of interdisciplinary collaboration in successful deprescribing efforts.
Guidelines such as the Beers Criteria and STOPP/START criteria provide valuable frameworks for identifying potentially inappropriate medications in older adults. A study by O'Mahony et al. (2015) found that applying these criteria can reduce inappropriate prescribing and improve medication safety [PMID: 26446832].
Caveats and uncertainty
While deprescribing offers clear benefits, it is not without challenges. Potential barriers include patient resistance, fear of withdrawal effects, and the complexity of managing multiple comorbidities. The process requires careful assessment of the risks and benefits of discontinuing each medication, considering the patient's overall health status and treatment goals.
The evidence base for deprescribing is growing, but variability in study designs and patient populations can limit the generalizability of findings. Further research is needed to establish standardized protocols and to explore the long-term effects of deprescribing on health outcomes.
The success of deprescribing initiatives is highly dependent on effective communication and shared decision-making between patients and healthcare providers. Ensuring that patients understand the rationale for deprescribing and are actively involved in the process is crucial for adherence and satisfaction.
How this may change practice
The integration of deprescribing strategies into routine clinical practice can enhance medication management and reduce the risks associated with polypharmacy in older adults. Clinicians should incorporate evidence-based guidelines and tools, such as the Beers and STOPP/START criteria, into medication reviews to identify candidates for deprescribing.
Interdisciplinary collaboration, involving pharmacists, physicians, and other healthcare providers, is essential to support comprehensive medication management and to address the complexities of deprescribing in older adults.
As awareness of the benefits of deprescribing grows, healthcare systems may increasingly prioritize training and resources to support these initiatives, ultimately improving the quality of care for older patients.